FREEHOLD, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong Intellectual Property Department (HKIPD) for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology.
Avalon GloboCare Announces Patent Issuance for Novel CAR-T and CAR-NK Cell Technology in Hong Kong
Seeking Alpha / 5 hours ago 2 Views
Comments